Recent Updates — INDV

Indivior Pharmaceuticals reported third-quarter 2026 total net revenue of $356 million, a 13% increase year-over-year, driven by record SUBLOCADE net revenue of $267 million, up 22%. GAAP net income reached $137 million ($1.12 diluted EPS), while adjusted EBITDA rose 76% to $211 million. The company confirmed it is on track to close its all-stock merger with Supernus Pharmaceuticals on November 2, 2026, after shareholders approved the transaction in October. Indivior operates as a leader in long-acting injectable treatments for opioid use disorder.

At a special meeting on October 15, 2026, Indivior Pharmaceuticals stockholders approved the issuance of shares in connection with a pending merger agreement. The proposal received 85,455,705 votes in favor against 5,563,744, representing approximately 93.6% of votes cast by the 77.27% quorum present. This approval is required to comply with Nasdaq Rule 5635 regarding share issuance for business combinations. Indivior Pharmaceuticals operates in the pharmaceutical industry, focusing on addiction treatment therapies.

Indivior Pharmaceuticals and Supernus Pharmaceuticals filed a supplement to their joint proxy statement/prospectus regarding the proposed merger. The filing updates valuation analyses by financial advisor Cantor Fitzgerald, adjusting for estimated cash, debt, and a $1 billion special dividend paid by Indivior. This disclosure follows demand letters and complaints from purported stockholders alleging incomplete information in the original proxy materials. Both companies deny any wrongdoing but voluntarily supplemented the disclosures to moot litigation claims and avoid delays to the merger. Special meetings of stockholders for both companies are scheduled for October 15, 2026, to vote on the transaction. Indivior Pharmaceuticals is a pharmaceutical company focused on addiction treatment therapies.

Indivior Pharmaceuticals declared a special cash dividend of $8.13 per share for common stockholders and holders of certain equity awards, contingent upon the closing of its merger with Supernus Pharmaceuticals. The record date is October 30, 2026, with payment anticipated on or about November 6, 2026, assuming the merger closes around November 2, 2026. Indivior operates in the pharmaceutical industry, specializing in long-acting injectable treatments for opioid use disorder.

Indivior Pharmaceuticals, Inc. announced the execution of a definitive Agreement and Plan of Merger with Supernus Pharmaceuticals, Inc., creating a $2.2 billion diversified central nervous system biopharmaceutical leader through a 100% tax-free stock-for-stock transaction. Under the terms, Supernus shareholders will receive 1.5401 Indivior shares for each Supernus share, resulting in an ownership split of 56.5% for Indivior and 43.5% for Supernus post-close. Prior to closing, Indivior will declare a $1 billion aggregate special cash dividend to pre-closing stockholders, funded by approximately $650 million in additional debt. The combined entity will feature an expanded executive team led by Supernus CEO Jack Khattar and a board with four directors from each company. The transaction targets closing in Q4 2026, subject to shareholder and regulatory approvals, and anticipates at least $125 million in annual cost synergies based on pro forma LTM net revenues of $2.16 billion as of June 30, 2026. Indivior Pharmaceuticals operates in the pharmaceutical industry, specializing in treatments for opioid use disorder.